OLGT 2024-64: Cross Programs: Pediatric RISE in High-Risk Neuroblastoma Program

Dana Farber Cancer Institute will offer the Pediatric RISE program to families participating in a multi-center clinical trial for high-risk neuroblastoma. The program, Pediatric RISE in High-Risk Neuroblastoma, builds on health equity research, hypothesizing that reducing poverty-related stress will improve cancer outcomes. Eligible families with incomes at or below 200% of the federal poverty level will receive six months of cash support.

The randomized study, enrolling 84 families across 10 U.S. centers, will begin October 2024 to March 2028. Income received from the Pediatric RISE in High-Risk Neuroblastoma program is non-countable for all DTA programs.